Cargando…

The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular Biomarkers

The evaluation of treatment response remains a challenge in glioma cases because the neuro oncological therapy can lead to the development of treatment-related changes (TRC) that mimic true progression (TP). Positron emission tomography (PET) using O-(2-[(18)F] fluoroethyl-)-L-tyrosine ((18)F-FET) h...

Descripción completa

Detalles Bibliográficos
Autores principales: Skoblar Vidmar, Marija, Doma, Andrej, Smrdel, Uroš, Zevnik, Katarina, Studen, Andrej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224265/
https://www.ncbi.nlm.nih.gov/pubmed/35743228
http://dx.doi.org/10.3390/ijms23126787
_version_ 1784733322866327552
author Skoblar Vidmar, Marija
Doma, Andrej
Smrdel, Uroš
Zevnik, Katarina
Studen, Andrej
author_facet Skoblar Vidmar, Marija
Doma, Andrej
Smrdel, Uroš
Zevnik, Katarina
Studen, Andrej
author_sort Skoblar Vidmar, Marija
collection PubMed
description The evaluation of treatment response remains a challenge in glioma cases because the neuro oncological therapy can lead to the development of treatment-related changes (TRC) that mimic true progression (TP). Positron emission tomography (PET) using O-(2-[(18)F] fluoroethyl-)-L-tyrosine ((18)F-FET) has been shown to be a useful tool for detecting TRC and TP. We assessed the diagnostic performance of different (18)F-FET PET segmentation approaches and different imaging biomarkers for differentiation between late TRC and TP in glioma patients. Isocitrate dehydrogenase (IDH) status was evaluated as a predictor of disease outcome. In our study, the proportion of TRC in IDH wild type (IDHwt) and IDH mutant (IDHm) subgroups was without significant difference. We found that the diagnostic value of static and dynamic biomarkers of (18)F-FET PET for discrimination between TRC and TP depends on the IDH mutation status of the tumor. Dynamic (18)F-FET PET acquisition proved helpful in the IDH wild type (IDHwt) subgroup, as opposed to the IDH mutant (IDHm) subgroup, providing an early indication to discontinue dynamic imaging in the IDHm subgroup.
format Online
Article
Text
id pubmed-9224265
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92242652022-06-24 The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular Biomarkers Skoblar Vidmar, Marija Doma, Andrej Smrdel, Uroš Zevnik, Katarina Studen, Andrej Int J Mol Sci Communication The evaluation of treatment response remains a challenge in glioma cases because the neuro oncological therapy can lead to the development of treatment-related changes (TRC) that mimic true progression (TP). Positron emission tomography (PET) using O-(2-[(18)F] fluoroethyl-)-L-tyrosine ((18)F-FET) has been shown to be a useful tool for detecting TRC and TP. We assessed the diagnostic performance of different (18)F-FET PET segmentation approaches and different imaging biomarkers for differentiation between late TRC and TP in glioma patients. Isocitrate dehydrogenase (IDH) status was evaluated as a predictor of disease outcome. In our study, the proportion of TRC in IDH wild type (IDHwt) and IDH mutant (IDHm) subgroups was without significant difference. We found that the diagnostic value of static and dynamic biomarkers of (18)F-FET PET for discrimination between TRC and TP depends on the IDH mutation status of the tumor. Dynamic (18)F-FET PET acquisition proved helpful in the IDH wild type (IDHwt) subgroup, as opposed to the IDH mutant (IDHm) subgroup, providing an early indication to discontinue dynamic imaging in the IDHm subgroup. MDPI 2022-06-17 /pmc/articles/PMC9224265/ /pubmed/35743228 http://dx.doi.org/10.3390/ijms23126787 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Skoblar Vidmar, Marija
Doma, Andrej
Smrdel, Uroš
Zevnik, Katarina
Studen, Andrej
The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular Biomarkers
title The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular Biomarkers
title_full The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular Biomarkers
title_fullStr The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular Biomarkers
title_full_unstemmed The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular Biomarkers
title_short The Value of FET PET/CT in Recurrent Glioma with a Different IDH Mutation Status: The Relationship between Imaging and Molecular Biomarkers
title_sort value of fet pet/ct in recurrent glioma with a different idh mutation status: the relationship between imaging and molecular biomarkers
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224265/
https://www.ncbi.nlm.nih.gov/pubmed/35743228
http://dx.doi.org/10.3390/ijms23126787
work_keys_str_mv AT skoblarvidmarmarija thevalueoffetpetctinrecurrentgliomawithadifferentidhmutationstatustherelationshipbetweenimagingandmolecularbiomarkers
AT domaandrej thevalueoffetpetctinrecurrentgliomawithadifferentidhmutationstatustherelationshipbetweenimagingandmolecularbiomarkers
AT smrdeluros thevalueoffetpetctinrecurrentgliomawithadifferentidhmutationstatustherelationshipbetweenimagingandmolecularbiomarkers
AT zevnikkatarina thevalueoffetpetctinrecurrentgliomawithadifferentidhmutationstatustherelationshipbetweenimagingandmolecularbiomarkers
AT studenandrej thevalueoffetpetctinrecurrentgliomawithadifferentidhmutationstatustherelationshipbetweenimagingandmolecularbiomarkers
AT skoblarvidmarmarija valueoffetpetctinrecurrentgliomawithadifferentidhmutationstatustherelationshipbetweenimagingandmolecularbiomarkers
AT domaandrej valueoffetpetctinrecurrentgliomawithadifferentidhmutationstatustherelationshipbetweenimagingandmolecularbiomarkers
AT smrdeluros valueoffetpetctinrecurrentgliomawithadifferentidhmutationstatustherelationshipbetweenimagingandmolecularbiomarkers
AT zevnikkatarina valueoffetpetctinrecurrentgliomawithadifferentidhmutationstatustherelationshipbetweenimagingandmolecularbiomarkers
AT studenandrej valueoffetpetctinrecurrentgliomawithadifferentidhmutationstatustherelationshipbetweenimagingandmolecularbiomarkers